Parkinson’s disease
is a progressive neurodegenerative disorder characterized by damage of
dopaminergic neurons located in various parts of brain including the substantia
nigra. This lowers the concentration of dopamine in the striatum. A decrease in
dopamine levels by 80 percent leads to the development of symptoms associated
with Parkinson’s disease such as tremor, bradykinesia, and muscular rigidity.
It is usually diagnosed in the population aged 60 and over; however, earlier
incidences have been reported. Based on the severity, it can be categorized
into early stage, mid stage and late (or advanced) stage. Currently, the
approved therapies provide only symptomatic relief. Levodopa is the standard
drug for the treatment of Parkinson’s disease; however, it is associated with
the incidence of dyskinesias. Alternative surgical procedures such as bilateral
globus pallidus interna stimulation and bilateral subthalamic nucleus
stimulation can be used in Parkinson’s disease patients under certain
circumstances.
Analysts forecast
the Global Parkinson’s
Disease market will grow at a
CAGR of 3.32 percent over the period 2013-2018.
The Report
recognizes the following companies as the key players in the Global Parkinson’s
Disease market: Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Novartis AG and
Teva Pharmaceutical Industries Ltd.
Other prominent
vendors in this market are: Abbvie Inc., Akorn Inc., Astellas Pharma Inc., Desitin
Arzneimittel GmbH, Endo International plc, F. Hoffmann-La Roche Ltd., H.
Lundbeck A/S, Kyowa Hakko Kirin, Merck & Co. Inc., Orion Corp., STADA
Arzneimittel AG, UCB Inc., US WorldMeds LLC, Valeant Pharmaceuticals
International Inc.
One of the emerging
trends that is expected in the market is the reformulation of marketed drugs.
Reformulation is generally aimed at reducing the side effects associated with
conventional dosage forms. This, in turn, increases patient compliance and the
market revenue of the drug.
Covered in this Report
This report covers
the present scenario and the growth prospects of the Global Parkinson’s Disease
market for the period 2014-2018. To calculate the market size, the report
considers revenue generated through the sales of various drugs administered to
provide symptomatic relief in Parkinson’s disease.
The report also
presents the vendor landscape and a corresponding detailed analysis of the top
four vendors in the Global Parkinson’s Disease market. In addition, it
discusses the major drivers that influence the growth of the market. It also
outlines the challenges faced by the vendors and the market at large, as well
as the key trends that are emerging in the market.
Global Parkinson’s
Disease Market 2014-2018, has been prepared based on an in-depth market
analysis with inputs from industry experts. The report covers the Americas and
the EMEA and APAC regions; it also covers the Global Parkinson’s Disease market
landscape and its growth prospects in the coming years. The report also
includes a discussion of the key vendors operating in this market.
According to the
report, the Global Parkinson’s Disease market is driven by several factors, of
which the increase in the aging population is one of the major drivers. The
incidence rate of Parkinson’s disease is growing continuously, mainly because
of the increase in the aging population, especially those in the age group of
60 years and more.
Further, the report
states that one of the main challenges that the market faces is the increasing
generic erosion of already marketed drugs. Generic drugs provide a low-cost
alternative to innovator drugs and, hence, are preferred over these drugs.
This, in turn, decreases the market sales of innovator drugs.
